PMV Pharmaceuticals Inc (OQ:PMVP)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: One Research Way
PRINCETON NJ 08540
Tel: N/A
Website: https://www.pmvpharma.com
IR: See website
<
Key People
David H. Mack
President, Chief Executive Officer, Co-Founder, Director 		Michael Carulli
Chief Financial Officer, Principal Accounting Officer 		Leila Alland
Chief Marketing Officer
Deepika Jalota
Chief Regulatory, Quality Assurance Officer 		   
Business Overview
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.
Financial Overview
For the fiscal year ended 31 December 2023, PMV Pharmaceuticals Inc revenues was not reported. Net loss decreased 6% to $69M. Lower net loss reflects Interest income increase from $3.6M to $11.2M (income), Research and development decrease of 5% to $37M (expense), General and administrative decrease of 5% to $17.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.61 to -$1.44.
Employees: 63 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$78.88M as of Dec 31, 2023
Net annual income (TTM): -$68.96M as of Dec 31, 2023
Free cash flow (TTM): -$56.62M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 51,443,488 as of Feb 28, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More